Keio University School of Medicine

First Patient Dosed in Groundbreaking Optogenetic Gene Therapy Trial for Retinitis Pigmentosa

3 months ago

• Restore Vision Inc. has initiated the world's first clinical trial of optogenetic gene therapy using "Chimeric Rhodopsin" technology for treating retinitis pigmentosa patients. • The Phase I/II trial commenced at Keio University Hospital, utilizing RV-001, an AAV-vector-delivered gene therapy administered through intravitreal injection to restore light sensitivity. • The innovative gene-agnostic approach targets over 2 million people worldwide affected by retinitis pigmentosa, offering potential treatment regardless of genetic subtype.